VYNE Therapeutics Inc.
VYNE
$0.36
-$0.01-2.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.67M | -38.55M | -42.20M | -39.83M | -34.00M |
| Total Depreciation and Amortization | 22.00K | 16.00K | 10.00K | 4.00K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.25M | 1.14M | 1.09M | 859.00K | 1.16M |
| Change in Net Operating Assets | -5.96M | -2.38M | 3.64M | 5.00M | 2.73M |
| Cash from Operations | -38.36M | -39.77M | -37.45M | -33.97M | -30.11M |
| Capital Expenditure | -117.00K | -117.00K | -117.00K | -117.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.76M | 32.54M | 46.88M | 23.48M | -51.73M |
| Cash from Investing | 41.65M | 32.42M | 46.77M | 23.37M | -51.73M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 82.67M |
| Repurchase of Common Stock | -260.00K | -255.00K | -223.00K | -141.00K | -11.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -260.00K | -255.00K | -223.00K | -141.00K | 82.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.03M | -7.61M | 9.09M | -10.75M | 817.00K |